Skip to content

Progression to castration-resistance and metastatic disease following androgen deprivation therapy for biochemical recurrence after prostate cancer surgery.

Oct 2026 · Cancer Epidemiology, Biomarkers and Prevention · pp. OF1-OF8 · 0 citations
Medicine

TL;DR

In this large national cohort of men with biochemical recurrence after surgery, most did not develop metastatic disease during nearly 10 years of follow up and one in four patients were treated with androgen deprivation therapy.

Abstract

Background

Biochemical recurrence after radical prostatectomy for localized prostate cancer impacts nearly one in four patients. While androgen deprivation therapy (ADT) is used in this setting, its impact on metastatic disease outcomes remains unclear in contemporary population-based cohorts.

Methods

We performed a retrospective cohort study using national Veterans Administration electronic health record and Central Cancer Registry data. Men undergoing radical prostatectomy between 2005-2015 were followed through 2019. We defined biochemical recurrence as prostate-specific antigen (PSA) ≥0.20 nanograms/milliliter. We examined biochemically recurrent prostate cancer management and disease progression to castration-resistance and metastatic disease.

Results

Of 28,452 men with prostate cancer treated surgically, 7,912 (28%) developed biochemical recurrence with 10.5% developing metastatic disease (median follow up 110 months). Salvage ADT with or without radiation therapy was administered to 24% of patients. In adjusted models, salvage ADT use was associated with worse metastasis-free survival (adjusted hazard ratio (aHR) 1.96, 95% CI 1.71-2.25) and increased castration resistant therapy (aHR 20.51, 95% CI 14.48-29.04). Higher pathologic T stage, Gleason grade group, PSA, nodal involvement, and faster PSA doubling times were predictive of metastasis.

Conclusions

In this large national cohort of men with biochemical recurrence after surgery, most did not develop metastatic disease during nearly 10 years of follow up and one in four patients were treated with ADT. The association between ADT and adjusted outcomes likely reflects more aggressive disease among men selected for hormonal therapy. IMPACT These findings underscore the importance of continued risk stratification refinement and management optimization for recurrent prostate cancer.

View source

Similar papers

Open access Sep 2026

Association Between Castration-resistant Prostate Cancer Progression Patterns and Survival Outcomes in Metastatic Castration-sensitive Prostate Cancer: A Post Hoc Analysis of the TITAN Trial.

BACKGROUND AND OBJECTIVE In metastatic castration-sensitive prostate cancer, the prognostic implications of castration-resistant prostate cancer (CRPC) progression patterns under upfront androgen receptor signaling inhibitors remain unclear. We evaluated the prognostic impact of CRPC subtypes and baseline predictors us...

Tomohiro Hori, H. Iwamoto, Takahiro Inaba et al. · 0 citations
Review Open access Oct 2026

Prostate-directed Radiotherapy in Selected Patients With Metastatic Castration-sensitive Prostate Cancer: A Real-world Case Series

In this small, highly selected cohort of patients demonstrating favorable initial responses to systemic therapy, prostate-directed RT was feasible and well tolerated, with no grade ≥2 acute RT-related toxicity, no late toxicity among evaluable patients, and no local events.

N. Furubayashi, Takaaki Nakashima, Ryuji Uehara et al. · 0 citations
Review Open access Oct 2026

Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative Review

In post-prostatectomy prostate cancer, combining androgen deprivation therapy (ADT) with salvage radiotherapy (SRT) significantly improves clinical outcomes, though the absolute benefit varies based on baseline PSA, pathological risk, and treatment design. This review synthesizes findings from key randomized trials and...

B. D'Andrea, A. Montagna, I. Benevento et al. · 0 citations
Open access Sep 2026

Absolute Benefit of Androgen Deprivation Therapy With Radiotherapy for Localized Prostate Cancer

Objectives: To estimate the absolute benefit of adding and prolonging androgen deprivation therapy (ADT) to radiation therapy (RT) for men with localized prostate cancer by integrating cancer-specific risk, other-cause mortality (OCM) risk, and relative treatment efficacy. Subjects and Methods: Individualized risks wer...

Jessica Aldous, W. Jackson, Elizabeth Chase et al. · 0 citations
Oct 2026

Abstract B056: Comparative efficacy of definitive radiotherapy and radical prostatectomy in African American men with high-risk and very high-risk prostate cancer: A real-world institutional cohort study

African American (AA) men experience the highest incidence and mortality from prostate cancer in the United States and are more likely to be diagnosed with aggressive disease. However, evidence comparing definitive treatment strategies for high-risk localized prostate cancer in AA men remains limited. We compared...

Muhammad Umar Afzal, Ewan K. Cobran, Syed Arsalan Ahmed Naqvi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.